US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Italy-UAE space cooperation is shifting from procurement to co-development as the UAE builds sovereign AI-driven and industrial capabilities. Combining Italian engineering with Emirati capital and ...
Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...
If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...
Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...
Company enters 2026 focused on disciplined expansion, national partnerships, and scalable solutions to the growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback